Figure 2

Malignant B cells in SLL/CLL have higher basal levels of phospho-proteins. Scatter plots of the basal level of 8 phospho-proteins in malignant B cells from SLL/CLL patients (SLL/CLL, n = 11), MZL patients (MZL, n = 3). Unstimulated samples were used for analysis of basal level of phospho-proteins. MFI for each phospho-protein in the CD20⁺CD5⁺ (SLL/CLL) or CD20⁺ subset (MZL) were normalized to MFI in the CD20⁺ B cell subset from healthy blood donor PBMC analyzed at the same time. * indicates significant change from normal CD 20⁺ B cells, p < 0.05; Wilcoxon Signed Rank test.